BioSpace News Archive

Hummingbird Bioscience announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) today announced that it presented additional data from its two ongoing Phase 2 clinical trials of KER-050, one in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”) and one in patients with myelofibrosis (“MF”), at the 65th American Society of Hematology (“ASH”) Annual Meeting and Exposition.

cultivate(MD), a leader in medical device venture capital, is thrilled to announce that one of its portfolio companies, NSite Medical, has received FDA clearance for its groundbreaking AI-based scoliosis scanning application.

NRx Pharmaceuticals, Inc. today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8th through the 10th in San Francisco.

Merck & Co. and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157).

Basilea Pharmaceutica Ltd announced that its license partner Astellas Pharma US, Inc. received the approval of Cresemba® for the treatment of invasive aspergillosis and invasive mucormycosis in pediatric patients by the US Food and Drug Administration.

Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology.

MaaT Pharma presented positive results from the Early Access Program in Europe involving 111 patients with steroid-refractory or steroid-dependent gastrointestinal acute graft-versus-host Disease treated with MaaT013, at the 2023 American Society of Hematology Annual Meeting.

Glycotope GmbH has signed an agreement with Evotec SE to combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced updated data on its lead innate cell engager acimtamig.